<DOC>
	<DOCNO>NCT03014804</DOCNO>
	<brief_summary>This phase II trial study side effect autologous dendritic cell pulse tumor lysate antigen vaccine nivolumab see well work treat patient glioblastoma come back . Vaccines make person 's tumor cell may help body build effective immune response kill tumor cell . Monoclonal antibody , nivolumab , may interfere ability tumor cell grow spread . Giving dendritic cell-autologous lung tumor vaccine nivolumab may work well treat patient glioblastoma .</brief_summary>
	<brief_title>Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Vaccine Nivolumab Treating Patients With Recurrent Glioblastoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To evaluate safety tolerability combination treatment autologous dendritic cell pulse tumor lysate antigen vaccine ( DCVax-L ) nivolumab . II . To compare overall survival ( OS ) date surgery pool evaluation group 1 subject receive DCVax-L group 2 subject receive DCVax-L nivolumab recent historical standard . III . To compare OS two group . SECONDARY OBJECTIVES : I . Safety . II . Feasibility . III . Tumor response . IV . Immune response . V. Quality Life ( QoL ) . VI . Overall survival ( OS ) . VII . Overall survival rate 9 , 12 , 18 month . VIII . Progression-free survival ( PFS ) . IX . Evaluation safety DCVax-L + nivolumab combination regimen . TERTIARY OBJECTIVES : I . Estimate correlation quantitative assessment tumor-infiltrating lymphocyte ( TIL ) proliferation ( CD8+/Ki-67+ stain ) . II . Estimate difference PD-1 PD-L1 immunohistochemistry expression density clonality clinical response combination therapy recurrent glioblastoma subject . III . Estimate differences outcome group monocytic PD-L1 expression baseline time . IV . Estimate differences outcome group circulate tumor DNA , circulate tumor cell , CD4+ T cell baseline time . V. Estimate difference PD-1 PD-L1 immunohistochemical ( IHC ) expression archive study sample . VI . Explore pattern tumor proteomic profiling . VII . Estimate efficacy combination therapy progression-free survival ( PFS ) , rate contrast tumor change time , overall survival ( OS ) . VIII . Explore effect nivolumab TIL proliferation ( CD8+/Ki-67+ stain ) . IX . Explore whether oligoclonal T cell population within tumor tissue similarly expand peripheral blood nivolumab , magnitude correlate clinical response . X . Explore change specific MRI parameter correlate tumor peripheral blood immune response . XI . Explore mesenchymal gene expression signature present initial archive tumor sample correlate T lymphocytic response tumor nivolumab . XII . Correlate change positron emission tomography ( PET ) tumor follow : TIL density clonality , clinical outcome , T cell measure peripheral blood , clinical toxicity . XIII . Correlate change PET lymph node follow : TIL density clonality , clinical outcome , T cell measure peripheral blood , clinical toxicity . XIV . Correlate change PET organ tissue TIL density clonality . OUTLINE : Patients randomize 1 2 group . GROUP I : Patients receive dendritic cell-autologous lung tumor vaccine intradermally ( ID ) day 0 , 7 , 14 , week 4 , 6 , 8 , 11 , 14 , 17 20 . GROUP II : Patients receive dendritic cell-autologous lung tumor vaccine Group I , nivolumab intravenously ( IV ) 30 minute day 0 , 14 , week 4 , 6 , 8 , 11 , 14 , 17 , 20 . After completion study treatment , patient follow 12 month .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Gliosarcoma</mesh_term>
	<mesh_term>Oligodendroglioma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<criteria>PRESURGERY SCREENING PROCESS Original diagnosis glioblastoma multiforme ( GBM ) confirm central review Radiographic evidence first recurrence per Response Assessment NeuroOncology ( RANO ) criterion confirm central review Surgically accessible , unilateral , recurrent GBM tumor extirpative resection , intent perform gross total near gross total resection , indicate ; subject may screen previous biopsy schedule subsequent gross near gross total resection prior commencement therapy Ability understand sign tumor procurement inform consent form indicate awareness investigational nature study ; consent tumor tissue donation may sign legally authorize representative ( LAR ) allow institution Life expectancy &gt; = 12 week Absolute lymphocyte count &gt; = 0.6 x 10^3/mm^3 ( 0.6 x 10^9/L ) MGMT promoter methylation status original tumor obtainable POSTSURGERY , PRIOR TO PRELEUKAPHERESIS Therapy recurrent disease must consist surgical resection extend beyond biopsy , intent achieve gross neartotal resection contrastenhancing tumor mass ; subject underwent resection confirm beyond biopsy remain eligible screening process ; subject undergo biopsy exclude ; central confirmation require subject proceed leukapheresis Patients recurrent unilateral GBM , confirm central pathology ( grade IV ) , without metastasis , remain eligible protocol For purpose study , pathology report histologically confirm GBM include recognize variant glioblastoma ( small cell glioblastoma , giant cell glioblastoma , gliosarcoma , glioblastoma oligodendroglial component ) All subject must sufficient tumor lysate protein generate resected tumor tissue ; determination make sponsor 's contracted manufacturer communicate clinical site sponsor designee ; confirmation require prior preleukapheresis visit , require subject proceed leukapheresis PRELEUKAPHERESIS EVALUATION Hemoglobin &gt; 10 g/dL ( 100 g/L ) White blood cell count 3.611.0 x 10^3/mm^3 ( 3.611.0 x 10^9/L ) Absolute granulocyte count &gt; = 1.5 x 10^3/mm^3 ( 1.5 x 10^9/L ) Absolute lymphocyte count &gt; = 1.0 x 10^3/mm^3 ( 1.0 x 10^9/L ) Platelet count &gt; = 100 x 10^3/mm^3 ( 100 x 10^9/L ) Eligibility maintain laboratory result outside central laboratory 's normal reference range sample range provide deem clinically significant treat investigator Eligibility level hemoglobin reach transfusion ; value determine central laboratory Serum glutamate pyruvate transaminase ( SGPT ) = &lt; 4.0 time upper limit normal ( ULN ) Serum glutamicoxaloacetic transaminase ( SGOT ) = &lt; 4.0 time ULN Alkaline phosphatase = &lt; 4.0 time upper limit normal ( ULN ) Total bilirubin = &lt; 1.5 mg/dL ( 25.7 umol/L ) Blood urea nitrogen ( BUN ) = &lt; 1.5 time ULN Creatinine = &lt; 1.5 time ULN Subjects must Karnofsky performance status ( KPS ) rating &gt; = 70 preleukapheresis visit PRIOR TO DAY 0 Subjects may receive steroid therapy part primary treatment ; steroid treatment stop , continue steroid use clinically indicate , taper 2 mg dexamethasone per day ( equivalent ) least 7 day prior first immunization White blood cell count &gt; = 2.0 x 10^3/mm^3 ( 2.0 x 10^9/L ) Neutrophils &gt; = 1.5 x 10^3/mm^3 ( 1.5 x 10^9/L ) Platelets &gt; = 100 x 10^3/mm^3 ( 100 x 10^9/L ) Hemoglobin &gt; = 9.0 g/dL ( 90 g/L ) Serum creatinine = &lt; 1.5 x upper limit normal ( ULN ) SGOT ( aspartate aminotransferase [ AST ] ) = &lt; 3 x ULN SGPT ( alanine aminotransferase [ ALT ] ) = &lt; 3 x ULN Total bilirubin = &lt; 1.5 x ULN Except subject Gilbert 's syndrome , must total bilirubin &lt; 3.0 mg/dL Subjects must KPS rating &gt; = 60 preenrollment evaluation PRESCREENING Progression image base RANO criterion within 12 week conclusion radiotherapy History prior malignancy except adequately treat basal cell squamous cell skin cancer situ cervical cancer cancer deem fully resolve 5 year prior surgery History active , know , suspect autoimmune immunodeficiency disease Known human immunodeficiency virus ( HIV ) 1 2 human Tcell lymphotropic virus ( HTLV ) 1 2 positivity Active uncontrolled infection , sexually transmit disease ( STD ) , herpes , uncontrolled tuberculosis , malaria , etc Known intolerance cyclophosphamide alkylating agent , component study drug History active immunotherapy , include dendritic cell therapy , T cell therapy , immunization tumor antigens form , antiPD1 , antiPDL1 , antiPDL2 , antiCTLA4 antibody , antibody drug specifically target Tcell costimulation immune checkpoint pathway checkpoint inhibitor therapy ipilimumab History severe infusionrelated reaction biologics therapy Females gravid breastfeed Inability obtain informed consent psychiatric complicate medical problem Any know genetic cancersusceptibility syndromes Any positive test hepatitis B virus surface antigen ( HBV sAg ) hepatitis C virus ribonucleic acid ( HCV antibody ) indicative acute chronic infection AT OR AROUND SURGERY Bilateral metastatic glioblastoma detect diagnosis , surgery , postsurgical magnetic resonance imaging ( MRI ) ; tumor may cross , beyond , corpus callosum Postoperative MRI evidence biopsy , without significant tumor resection , confirmed central reviewer Implantation Gliadel wafer ( polifeprosan 20 carmustine implant ) surgery PRELEUKAPHERESIS VISIT Positive HIV1 , 2 , HTLV1 , 2 test Recipient organ allograft Allergies reagent use study Unable stop taper steroid treatment 2 mg dexamethasone per day ( equivalent ) prior leukapheresis ; steroid use stop tapered low clinically acceptable dose approximately 7 day prior leukapheresis ; leukapheresis visit must schedule occur minimum 21 day project day 0 It critical reduce steroid administration low possible dose , steroid interfere DCVaxL manufacturing hamper ability monocyte adhere plastic surface purification ; leukapheresis occur least 21 day prior project date DCVaxL administration Inability unwillingness return require visit followup exams EXCLUSION PRIOR TO DAY 0 Fewer 6 dos DCVaxL available administration Continued requirement medication might affect immune function ; follow exception : nonprescription strength dose NSAIDS , acetaminophen ( paracetamol ) , acetylsalicylic acid ( aspirin ) Acute infection : active viral , bacterial , fungal infection require specific therapy ; antibiotic therapy must complete least 7 day prior first DCVaxL/nivolumab administration Fever &gt; = 101.5 degree Fahrenheit ( F ) ( 38.6 degree Celsius [ C ] ) ; consider possibly transient , retesting allow Unstable severe intercurrent medical condition Women childbearing potential ( WOCBP ) pregnant lactate use adequate contraception willing avoid pregnancy 5 month week 20 visit Males sexually active WOCBP willing use contraceptive method failure rate le 1 % per year 7 month week 20 visit Any dose steroid exceed 10 mg/day prednisone ( equivalent ) within 2 week prior study drug administration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>